Anson Yeung

Oncology trainee in #hongkong. Also classical music lover.

[Karamvir Yadav @K_Yadavir]

LCNEC in 2026:
LCNEC ≠ just “SCLC variant.”

It’s biologically heterogeneous.
It behaves aggressively.
It relapses early.

Management snapshot:
✔ Resect → Adjuvant platinum–etoposide
✔ Stage III → ChemoRT ± durvalumab
✔ Metastatic → Platinum–etoposide ± ICI
✔ Profile every patient

DLL3 may change the landscape.

#ThoracicOncology #LCNEC @OncoThor @atscommunity @LungSummit @OncoAlert @oncodaily @ASCOPost @myESMO @hoperugo @NiuSanford @DraMartinezLago @Erman_Akkus @diegoadiazg @StephenVLiu @Latinamd @allisonoconn

[Uğur Özkerim @UOzkerim]

From surgery and platinum–etoposide
➡️ immunotherapy
➡️ molecular stratification
➡️ DLL3-targeted therapies

LCNEC management is evolving—but consensus is not.
Curious to hear how others approach this rare entity
@OncoAlert @OncBrothers @lungoncdoc
@OncoReporte @MedwatchKate @brunolarvol

[MV Chandrakanth @ChandrakanthMv]

• LCNEC ≠ NSCLC ≠ SCLC
• Rare. Aggressive. No large RCTs.
• Surgery, CRT, systemic therapy — all extrapolated
• PCI: routine or not? 👀
• DLL3: the next big target?
Adapted from Yeung & Chow, Clinical Lung Cancer 2026
#LCNEC #LungCancer #Neuroendocrine #MVOnco

[Anson Yeung @mlansonyeung]

Just published: our review on pulmonary LCNEC - a rare but aggressive & heterogeneous entity.
We review current evidence across all disease stages and emerging strategies including molecular profiling and DLL3-targeted therapy. @jameschowch
#LCNEC #LungCancer #Oncology

[Clinical Lung Cancer @ClinicalLung]

Pulmonary large-cell neuroendocrine carcinoma (LCNEC) is a rare and aggressive lung cancer with clinical/biological heterogeneity. Management is largely extrapolated from other lung cancer paradigms. Check out a recent review on this challenging disease.

https://t.co/69gYL24Dkq